Login to Your Account



Summit's oral DMD drug meets endpoint, moves to phase II

By Nuala Moran
Staff Writer

Monday, August 17, 2015
LONDON – Summit Therapeutics plc finally has cracked the problem of delivering SMT C1100, a universal treatment for DMD, opening the way for phase II development to start later this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription